271 related articles for article (PubMed ID: 31874858)
41. Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma.
Sabbatino F; Scognamiglio G; Liguori L; Marra A; Anniciello AM; Polcaro G; Dal Col J; Caputo A; Peluso AL; Botti G; Zeppa P; Ferrone S; Pepe S
Front Immunol; 2020; 11():561390. PubMed ID: 33117345
[TBL] [Abstract][Full Text] [Related]
42. Linking Transcriptomic and Imaging Data Defines Features of a Favorable Tumor Immune Microenvironment and Identifies a Combination Biomarker for Primary Melanoma.
Gartrell-Corrado RD; Chen AX; Rizk EM; Marks DK; Bogardus MH; Hart TD; Silverman AM; Bayan CY; Finkel GG; Barker LW; Komatsubara KM; Carvajal RD; Horst BA; Chang R; Monod A; Rabadan R; Saenger YM
Cancer Res; 2020 Mar; 80(5):1078-1087. PubMed ID: 31948941
[TBL] [Abstract][Full Text] [Related]
43. Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.
Xiao Y; Ma D; Zhao S; Suo C; Shi J; Xue MZ; Ruan M; Wang H; Zhao J; Li Q; Wang P; Shi L; Yang WT; Huang W; Hu X; Yu KD; Huang S; Bertucci F; Jiang YZ; Shao ZM;
Clin Cancer Res; 2019 Aug; 25(16):5002-5014. PubMed ID: 30837276
[TBL] [Abstract][Full Text] [Related]
44. Heme catabolism by tumor-associated macrophages controls metastasis formation.
Consonni FM; Bleve A; Totaro MG; Storto M; Kunderfranco P; Termanini A; Pasqualini F; Alì C; Pandolfo C; Sgambelluri F; Grazia G; Santinami M; Maurichi A; Milione M; Erreni M; Doni A; Fabbri M; Gribaldo L; Rulli E; Soares MP; Torri V; Mortarini R; Anichini A; Sica A
Nat Immunol; 2021 May; 22(5):595-606. PubMed ID: 33903766
[TBL] [Abstract][Full Text] [Related]
45. Identification of immune-related gene signature predicting survival in the tumor microenvironment of lung adenocarcinoma.
Zhao M; Li M; Chen Z; Bian Y; Zheng Y; Hu Z; Liang J; Huang Y; Yin J; Zhan C; Feng M; Wang Q
Immunogenetics; 2020 Dec; 72(9-10):455-465. PubMed ID: 33188484
[TBL] [Abstract][Full Text] [Related]
46. Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma.
Gide TN; Wilmott JS; Scolyer RA; Long GV
Clin Cancer Res; 2018 Mar; 24(6):1260-1270. PubMed ID: 29127120
[TBL] [Abstract][Full Text] [Related]
47. Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.
Kakavand H; Vilain RE; Wilmott JS; Burke H; Yearley JH; Thompson JF; Hersey P; Long GV; Scolyer RA
Mod Pathol; 2015 Dec; 28(12):1535-44. PubMed ID: 26403784
[TBL] [Abstract][Full Text] [Related]
48. Mechanisms of Resistance to Immune Checkpoint Blockade.
Liu D; Jenkins RW; Sullivan RJ
Am J Clin Dermatol; 2019 Feb; 20(1):41-54. PubMed ID: 30259383
[TBL] [Abstract][Full Text] [Related]
49. Analysis of immune subtypes based on immunogenomic profiling identifies prognostic signature for cutaneous melanoma.
Hu B; Wei Q; Zhou C; Ju M; Wang L; Chen L; Li Z; Wei M; He M; Zhao L
Int Immunopharmacol; 2020 Dec; 89(Pt A):107162. PubMed ID: 33168410
[TBL] [Abstract][Full Text] [Related]
50. COX-2 as a potential biomarker and therapeutic target in melanoma.
Tudor DV; Bâldea I; Lupu M; Kacso T; Kutasi E; Hopârtean A; Stretea R; Gabriela Filip A
Cancer Biol Med; 2020 Feb; 17(1):20-31. PubMed ID: 32296574
[TBL] [Abstract][Full Text] [Related]
51. PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors.
Kakavand H; Rawson RV; Pupo GM; Yang JYH; Menzies AM; Carlino MS; Kefford RF; Howle JR; Saw RPM; Thompson JF; Wilmott JS; Long GV; Scolyer RA; Rizos H
Clin Cancer Res; 2017 Oct; 23(20):6054-6061. PubMed ID: 28724663
[No Abstract] [Full Text] [Related]
52. Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types.
Bao R; Stapor D; Luke JJ
Genome Med; 2020 Oct; 12(1):90. PubMed ID: 33106165
[TBL] [Abstract][Full Text] [Related]
53. Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1.
Imbert C; Montfort A; Fraisse M; Marcheteau E; Gilhodes J; Martin E; Bertrand F; Marcellin M; Burlet-Schiltz O; Peredo AG; Garcia V; Carpentier S; Tartare-Deckert S; Brousset P; Rochaix P; Puisset F; Filleron T; Meyer N; Lamant L; Levade T; Ségui B; Andrieu-Abadie N; Colacios C
Nat Commun; 2020 Jan; 11(1):437. PubMed ID: 31974367
[TBL] [Abstract][Full Text] [Related]
54. Immune-escape markers in relation to clinical outcome of advanced melanoma patients following immunotherapy.
Tjin EP; Krebbers G; Meijlink KJ; van de Kasteele W; Rosenberg EH; Sanders J; Nederlof PM; van de Wiel BA; Haanen JB; Melief CJ; Vyth-Dreese FA; Luiten RM
Cancer Immunol Res; 2014 Jun; 2(6):538-46. PubMed ID: 24894091
[TBL] [Abstract][Full Text] [Related]
55. PTEN loss correlates with T cell exclusion across human cancers.
Lin Z; Huang L; Li SL; Gu J; Cui X; Zhou Y
BMC Cancer; 2021 Apr; 21(1):429. PubMed ID: 33874915
[TBL] [Abstract][Full Text] [Related]
56. Determination of hypoxia signature to predict prognosis and the tumor immune microenvironment in melanoma.
Shou Y; Yang L; Yang Y; Zhu X; Li F; Xu J
Mol Omics; 2021 Apr; 17(2):307-316. PubMed ID: 33624645
[TBL] [Abstract][Full Text] [Related]
57. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
[TBL] [Abstract][Full Text] [Related]
58. L Antigen Family Member 3 Serves as a Prognostic Biomarker for the Clinical Outcome and Immune Infiltration in Skin Cutaneous Melanoma.
Song J; Jin C; Chen E; Dong X; Zhu L
Biomed Res Int; 2021; 2021():6648182. PubMed ID: 33829062
[TBL] [Abstract][Full Text] [Related]
59. A digital score of tumour-associated stroma infiltrating lymphocytes predicts survival in head and neck squamous cell carcinoma.
Shaban M; Raza SEA; Hassan M; Jamshed A; Mushtaq S; Loya A; Batis N; Brooks J; Nankivell P; Sharma N; Robinson M; Mehanna H; Khurram SA; Rajpoot N
J Pathol; 2022 Feb; 256(2):174-185. PubMed ID: 34698394
[TBL] [Abstract][Full Text] [Related]
60. Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma.
Liu D; Yang X; Wu X
Front Immunol; 2021; 12():663495. PubMed ID: 34025664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]